Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin liposome + capecitabine + oxaliplatin + bevacizumab
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen consisting of pegylated liposomal doxorubicin (an anthracycline encapsulated in liposomes), capecitabine (a fluoropyrimidine), oxaliplatin (a platinum-based agent), and bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor). This combination leverages multiple mechanisms to target cancer cells and tumor vasculature.
- Other names
- Doxorubicin liposome combined with CapOX and BevacizumabDoxorubicin liposome + CapOX + Bevacizumab
02
Targets
DNATOP2B (DNA topoisomerase II beta)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin liposome + capecitabine + oxaliplatin + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin liposome + capecitabine + oxaliplatin + bevacizumab.